Last updated on July 21st, 2021 at 02:33 pm
Tatva Pharma IPO Subscription Status
What is the Subscription status for Tatva Pharma IPO?
[su_table]
| Subscription Status {no. of times (x)} | ||||
| Particulars | Shares Offered | 16th July | 19th July | 20th July |
| QIB | 9,31,966 | 0.50 | 1.97 | 185.23 |
| NII | 6,98,975 | 1.14 | 12.12 | 511.22 |
| Retail | 16,30,941 | 8.24 | 23.60 | 35.34 |
| Employees | – | – | ||
| Total | 32,61,882 | 4.51 | 14.95 | 180.35 |
[/su_table]
Tatva Pharma IPO Offer Details
How much is the retail category subscribed?
The retail category has been subscribed by 35.34 x on the last day of the offer.
Tatva Pharma -Should you subscribe?
What is the GMP for Tatva Pharma IPO?
GMP of Tatva Pharma IPO has risen to 65% i.e. at Rs 700-720 per share.
How much amount is raised from the anchor investors ahead of IPO?
Tatva Pharma has already raised Rs 150 crore from the anchor investors ahead of the IPO.
Who are the anchor investors for Tatva Pharma?
Tatva Chintan Pharma sold 13.85 lakh equity shares to anchor investors. Goldman Sachs, HSBC, Axis Mutual fund, Malabar India Fund, Nippon Life India, Abu Dhabi Investment Authority and Nomura Funds have each bought more than 6% of the anchor book portion. 47% or 6.46 lakh equity shares have been sold to seven domestic mutual funds which include ICICI Prudential, HDFC AMC, Axis Mutual Fund, Aditya Birla Sun Life, SBI, Nippon India, and Mirae Asset Hybrid.
When will the shares be credited to the Demat account?
Important dates for Tatva Pharma?
[su_table]
| Tatva Pharma IPO Allotment and Listing | |
| Basis of Allotment | 26-Jul-21 |
| Refunds | 27-Jul-21 |
| Credit to Demat Account | 28-Jul-21 |
| Listing Date | 29-Jul-21 |
[/su_table]
- One MobiKwik Systems Limited, MobiKwik IPO - 14/10/2021
- Bharti Airtel Rights Issue- Should You Subscribe? - 07/10/2021
- How to Check your IPO Allotment status? - 28/09/2021
Disclaimer: The above content is for general info purpose only and does not constitute professional advice. The author/ website will not be liable for any inaccurate / incomplete information and any reliance you place on the content is strictly at your risk.
Follow us on Social Media by clicking below
Follow @financepost_in
Be the first to comment